335653-59-3

Basic information

• Product Name: tert-butyl (1-(2,2,2-trifluoroethyl)piperidin-4-yl)carbaMate
• Synonyms: tert-butyl (1-(2,2,2-trifluoroethyl)piperidin-4-yl)carbaMate
• CAS NO: 335653-59-3
• Molecular Formula: C₁₂H₂₁F₃N₂O₂
• Molecular Weight: 282.3025496
• Mol File: 335653-59-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl (1-(2,2,2-trifluoroethyl)piperidin-4-yl)carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (1-(2,2,2-trifluoroethyl)piperidin-4-yl)carbaMate(335653-59-3)
• EPA Substance Registry System: tert-butyl (1-(2,2,2-trifluoroethyl)piperidin-4-yl)carbaMate(335653-59-3)

Safety Data

• Hazardous Substances Data: 335653-59-3(Hazardous Substances Data)

Upstream product

• 6226-25-1 2,2,2-trifluoroethyl trifluoromethanesulphonate 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 

Relevant articles and documents

1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS

A compound of formula (I), wherein R, R1, R2, R3, Y, Y1, a, X, and Z are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne Muscular Dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS

The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders

QUINOLINE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS

The present invention is directed to quinoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders

HALO-SUBSTITUTED PYRIMIDODIAZEPINES

The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.

Heteroalkylamino-substituted bicyclic nitrogen heterocycles

The invention provides compounds represented by the formula: wherein R1, R2, R3, R4, and n are as defined in the Summary of the Invention; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.